Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 8/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.75 |
| ▸ | HRH1 | P35367 | 6/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.75 |
| ▸ | HTR2A | P28223 | 5/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.75 |
| ▸ | DRD3 | P35462 | 5/20 | 0.75 |
| ▸ | HTR2B | P41595 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.75 |
| ▸ | RAD52 | P43351 | 5/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.75 |
| ▸ | HTR1A | P08908 | 4/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL144029 | 1.00 | LMNA (0.75) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069999 | 0.96 | LMNA (0.78) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL10394002 | 0.95 | LMNA (0.68) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL10394001 | 0.95 | LMNA (0.68) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069229 | 0.94 | LMNA (0.79) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1071642 | 0.91 | LMNA (0.84) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL246992 | 0.89 | MAPT (0.78) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL28456705 | 0.89 | MAPT (0.88) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| SCHEMBL21525461 | 0.89 | MAPT (0.76) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069230 | 0.88 | MAPT (0.76) | LMNAMAPTMAPK1HRH1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100129805-A1 | SLC1A1 ANTIPSYCHOTIC DRUG RESPONSE MARKERS | ASSUREX HEALTH, INC. | 2010-05-27 | — | — | US | claimed |
| US-7666597-B2 | Marker for tardive dyskinesia | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2010-02-23 | — | — | US | claimed |
| CN-101237878-A | Intralesional treatment of psoriasis | PHILADELPHIA HEALTH & EDUCATIO (US) | 2008-08-06 | — | — | CN | claimed |
| WO-2008055341-A1 | SLC1A1 ANTIPSYCHOTIC DRUG RESPONSE MARKERS | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2008-05-15 | — | — | WO | claimed |
| US-20080081019-A1 | Marker For Tardive Dyskinesia | CENTRE FOR ADDICTION AND MENTAL HEALTH, A CANADIAN COMPANY | 2008-04-03 | — | — | US | claimed |
| US-10435748-B2 | Genetic markers associated with suicide risk and methods of use thereof | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2019-10-08 | — | — | US | disclosed |
| EP-3087203-B1 | GENETIC MARKERS ASSOCIATED WITH SUICIDE RISK AND METHODS OF USE THEREOF | CAMH (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-20170002412-A1 | Genetic Markers Associated with Suicide Risk and Methods of Use Thereof | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2017-01-05 | — | — | US | disclosed |
| EP-3087203-A1 | GENETIC MARKERS ASSOCIATED WITH SUICIDE RISK AND METHODS OF USE THEREOF | Centre For Addiction And Mental Health (CA) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015095967-A1 | GENETIC MARKERS ASSOCIATED WITH SUICIDE RISK AND METHODS OF USE THEREOF | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2015-07-02 | — | — | WO | disclosed |
| US-20100129805-A1 | SLC1A1 ANTIPSYCHOTIC DRUG RESPONSE MARKERS | ASSUREX HEALTH, INC. | 2010-05-27 | — | — | US | disclosed |
| US-7666597-B2 | Marker for tardive dyskinesia | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2010-02-23 | — | — | US | disclosed |
| CN-101237878-A | Intralesional treatment of psoriasis | PHILADELPHIA HEALTH & EDUCATIO (US) | 2008-08-06 | — | — | CN | disclosed |
| WO-2008055341-A1 | SLC1A1 ANTIPSYCHOTIC DRUG RESPONSE MARKERS | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2008-05-15 | — | — | WO | disclosed |
| US-20080081019-A1 | Marker For Tardive Dyskinesia | CENTRE FOR ADDICTION AND MENTAL HEALTH, A CANADIAN COMPANY | 2008-04-03 | — | — | US | disclosed |